2008
DOI: 10.1016/j.diagmicrobio.2008.06.007
|View full text |Cite
|
Sign up to set email alerts
|

In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
10
1
1

Year Published

2009
2009
2022
2022

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 13 publications
(13 citation statements)
references
References 26 publications
1
10
1
1
Order By: Relevance
“…The percentage values ofresistance to levofloxacin are lower than those described by Seral et al (20), and higher than those reported by Biedenbach et al (18), Stefani et al (3), and Blasi et al (2). It should be noted that the phenomenon of constant increase of resistance to levofloxacin has been well described by Jones et al (28) and by Despande et al (29).…”
Section: Discussioncontrasting
confidence: 52%
See 3 more Smart Citations
“…The percentage values ofresistance to levofloxacin are lower than those described by Seral et al (20), and higher than those reported by Biedenbach et al (18), Stefani et al (3), and Blasi et al (2). It should be noted that the phenomenon of constant increase of resistance to levofloxacin has been well described by Jones et al (28) and by Despande et al (29).…”
Section: Discussioncontrasting
confidence: 52%
“…The MIC 90 values of 0.5 ug/ml, also observed by other Authors (20,37), could be particularly significant in terms of therapeutic predictivity (PKI PO), as they cover all the strains even at a dosage of 200 mg bid (9) without increasing the dose.…”
Section: Discussionmentioning
confidence: 54%
See 2 more Smart Citations
“…Trimethoprim/sulfamethasoxazole, azithromycin, clarithromycin, or erythromycin are recommended if the patient has a history of immediate type I hypersensitivity reaction to β-lactams [ 6 ]. Cefditoren pivoxil (CDT; Meiact, Meiji Seika Pharma Co., Tokyo, Japan) is a third-generation oral cephalosporin with good activity against respiratory tract pathogens, including penicillin-intermediate and penicillin-resistant strains of S. pneumoniae as well as beta-lactamase producing strains of H. influenzae and M. catarrhalis [ 7 , 8 , 9 , 10 , 11 ]. For CDT, as for β-lactams, the time (t) (expressed as percentage of the dosing interval) that antibiotic concentrations exceed the value of minimum inhibitory concentration (MIC) (t>MIC) is the index predicting efficacy with a cutoff value of 40% for clinical cure in humans [ 12 , 13 ].…”
Section: Introductionmentioning
confidence: 99%